Skip to content

Confirming feasibility of magnetic seizure therapy in the Dutch setting (CometD)

Confirming feasibility of magnetic seizure therapy in the Dutch setting (CometD) - CometD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON57471
Enrollment
10
Registered
2024-12-22
Start date
2025-08-05
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression melancholy depression

Interventions

Treatment with MST, applied at 100 Hz at 100% of the maximum device power for 8-10 seconds. Treatment will be continued until a clinical plateau is reached. We will use MRI and EEG measurements to i

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Eligible participants are men and women aged 18 and above who will be referred for treatment with ECT, have a major depressive episode in the context of MDD based on the Structured Clinical Interview for DSM-IV-TR.

Exclusion criteria

Exclusion criteria: Exclusion criteria will be a history of neurological disorders, head trauma, contraindications to MST, current unstable or serious medical illnesses, pregnancy or breastfeeding, history of ECT in the prior 6 months or failure to previously respond to ECT, or MOCA score lower than 22. More concrete contraindications with respect to the device are: Patients having conductive or any magnetic-sensitive materials implanted in the head or within 30cm of the treatment coil (examples: sutures, clips, coils, magnetic dental implants or implanted insulin pumps). Patients who have an implanted device that is activated or controlled in any way by physiological signals (examples: pacemakers, implantable cardioverter-defibrillators [ICD*s], vagus nerve stimulators [VNS] and wearable cardioverter-defibrillators [WCD*s], even when removed.

Design outcomes

Primary

MeasureTime frame
Our primary objective is to test the feasibility of MST.

Secondary

MeasureTime frame
Secondarily, we will descriptively describe the change of the depressive symptom scores of HRSD-17, cognitive scores and tolerability profile of MST patients. Additional endpoints concern changes in functional and structural brain connectivity (as measured with MRI and EEG) networks as a function of MST treatment to derive potential biomarkers for a future clinical trial.

Countries

Netherlands

Contacts

Public ContactI Tendolkar

Radboud Universitair Medisch Centrum

Indira.Tendolkar@radboudumc.nl0031243613489

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 9, 2026